TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Ascendis Pharma Oncology Division A/S
- Target Recruit Count
- 27
- Registration Number
- NCT05980598
- Locations
- 🇨🇳
Ascendis Investigational Site, Taoyuan, Taiwan
🇺🇸Ascendis Pharma Investigational Site, Canton, Ohio, United States
🇪🇸Ascendis Investigational Site II, Madrid, Spain
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Ascendis Pharma Oncology Division A/S
- Target Recruit Count
- 473
- Registration Number
- NCT05081609
- Locations
- 🇨🇳
Ascendis Pharma Investigational Site, Taipei, Taiwan
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Ascendis Pharma Oncology Division A/S
- Target Recruit Count
- 188
- Registration Number
- NCT04799054
- Locations
- 🇦🇺
Ascendis Pharma Investigational Site, Frankston, Victoria, Australia
🇨🇳Ascendis Investigational Site, Taipei City, Taiwan
© Copyright 2024. All Rights Reserved by MedPath